Payment overview · 2025
General Payments
$1,546.77
79 reported records · 18 companies
Healthcare provider profile · identity verified
Philipp C Wirth, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SENECA FALLS, NY · NPI 1194915389
Verified facts
What the public records show
CMS Open Payments records show Philipp C Wirth, MD received $1,546.77 in general payments during 2025 across 79 reported records.
Lilly USA, LLC accounted for 23.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Nurtec Odt, Ozempic, Paxlovid, Rybelsus, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 221 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 198 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $356.48 | 23.1% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $242.69 | 15.7% | 24 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $230.63 | 14.9% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $154.31 | 10.0% | 11 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $113.35 | 7.3% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $102.70 | 6.6% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $80.80 | 5.2% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $53.38 | 3.5% | 3 | 2025 |
| ALK-Abello, Inc | Unresolved — no canonical attribution shown | $42.28 | 2.7% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.45 | 2.5% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.92 | 1.4% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $20.43 | 1.3% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.12 | 1.3% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $13.84 | 0.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.65 | 0.9% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $13.63 | 0.9% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $13.61 | 0.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.50 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,462.77 | 78 |
| Education | $84.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $346.50 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $198.51 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $157.80 | 13 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $131.01 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $129.72 | 11 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $113.35 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $106.91 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $106.91 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $106.48 | 7 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $102.70 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $80.80 | 4 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ALK-Abello, Inc, ARS Pharmaceuticals Operations, Inc. | $62.71 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $47.03 | 6 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $47.03 | 6 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $47.03 | 6 | 2025 |
Source payment records
|
|||||
| Grastek Normalized: grastek |
Drug | ALK-Abello, Inc | $42.28 | 2 | 2025 |
Source payment records
|
|||||
| Odactra Normalized: odactra |
Drug | ALK-Abello, Inc | $42.28 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $39.45 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $37.86 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.75 | 2 | 2025 |
Source payment records
|
|||||
| SIMPONI Normalized: simponi |
Biological | Janssen Biotech, Inc. | $29.35 | 1 | 2025 |
Source payment records
|
|||||
| SIMPONI ARIA Normalized: simponi aria |
Biological | Janssen Biotech, Inc. | $29.35 | 1 | 2025 |
Source payment records
|
|||||
| STELARA Normalized: stelara |
Biological | Janssen Biotech, Inc. | $29.35 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $28.69 | 3 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $25.82 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.92 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.63 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $13.84 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.65 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.65 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $13.65 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $13.65 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $13.65 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $13.63 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $13.63 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $13.63 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $13.61 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 142 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 74 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 198 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 25 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 56 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 221 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
74 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
221 | 37 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
50 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
117 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
45 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
198 | 48 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
56 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
142 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
25 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1134 | 301 |
| Atorvastatin Calcium | Atorvastatin Calcium | 766 | 226 |
| Omeprazole | Omeprazole | 728 | 201 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 714 | 218 |
| Amlodipine Besylate | Amlodipine Besylate | 572 | 160 |
| Lisinopril | Lisinopril | 554 | 160 |
| Pantoprazole Sodium | Pantoprazole Sodium | 460 | 128 |
| Losartan Potassium | Losartan Potassium | 454 | 122 |
| Gabapentin | Gabapentin | 428 | 99 |
| Simvastatin | Simvastatin | 419 | 117 |
| Metoprolol Succinate | Metoprolol Succinate | 387 | 101 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 375 | 110 |
| Hydrochlorothiazide | Hydrochlorothiazide | 372 | 103 |
| Metformin Hcl | Metformin Hcl | 371 | 119 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 349 | 74 |
| Montelukast Sodium | Montelukast Sodium | 260 | 70 |
| Furosemide | Furosemide | 257 | 79 |
| Allopurinol | Allopurinol | 251 | 72 |
| Bupropion Xl | Bupropion Hcl | 240 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 225 | 73 |
| Duloxetine Hcl | Duloxetine Hcl | 223 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 223 | 59 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 221 | 37 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 211 | 60 |
| Escitalopram Oxalate | Escitalopram Oxalate | 206 | 56 |
| Ozempic | Semaglutide | 198 | 48 |
| Oxycodone Hcl | Oxycodone Hcl | 187 | 36 |
| Meloxicam | Meloxicam | 186 | 62 |
| Trazodone Hcl | Trazodone Hcl | 186 | 51 |
| Celecoxib | Celecoxib | 183 | 56 |
| Prednisone | Prednisone | 172 | 98 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 166 | 42 |
| Clonazepam | Clonazepam | 163 | 37 |
| Potassium Chloride | Potassium Chloride | 160 | 48 |
| Atenolol | Atenolol | 150 | 43 |
| Glipizide | Glipizide | 149 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 144 | 36 |
| Eliquis | Apixaban | 142 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 133 | 55 |
| Propranolol Hcl | Propranolol Hcl | 126 | 30 |
| Tramadol Hcl | Tramadol Hcl | 123 | 35 |
| Jardiance | Empagliflozin | 117 | 26 |
| Lorazepam | Lorazepam | 113 | 43 |
| Sertraline Hcl | Sertraline Hcl | 112 | 31 |
| Famotidine | Famotidine | 109 | 42 |
| Pregabalin | Pregabalin | 105 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 99 | 29 |
| Metformin Hcl Er | Metformin Hcl | 99 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 96 | 27 |
| Naproxen | Naproxen | 94 | 33 |
| Buspirone Hcl | Buspirone Hcl | 93 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 92 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 91 | 44 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 87 | 25 |
| Azithromycin | Azithromycin | 86 | 65 |
| Citalopram Hbr | Citalopram Hydrobromide | 85 | 22 |
| Warfarin Sodium | Warfarin Sodium | 84 | 24 |
| Spironolactone | Spironolactone | 79 | 27 |
| Farxiga | Dapagliflozin Propanediol | 74 | 19 |
| Finasteride | Finasteride | 74 | 19 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 71 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 71 | 19 |
| Baclofen | Baclofen | 70 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 24 |
| Ibuprofen | Ibuprofen | 69 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 68 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 66 | 18 |
| Alendronate Sodium | Alendronate Sodium | 64 | 15 |
| Synthroid | Levothyroxine Sodium | 63 | 19 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 60 | 17 |
| Ezetimibe | Ezetimibe | 60 | 16 |
| Mirtazapine | Mirtazapine | 60 | 12 |
| Diazepam | Diazepam | 59 | 16 |
| Glimepiride | Glimepiride | 59 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 59 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 59 | 15 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 57 | 14 |
| Rybelsus | Semaglutide | 56 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 54 | 16 |
| Tadalafil | Tadalafil | 54 | 11 |
| Irbesartan | Irbesartan | 53 | 14 |
| Linzess | Linaclotide | 53 | 11 |
| Carvedilol | Carvedilol | 52 | 17 |
| Cefdinir | Cefdinir | 51 | 40 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 51 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 50 | suppressed |
| Xarelto | Rivaroxaban | 50 | 17 |
| Topiramate | Topiramate | 49 | 14 |
| Januvia | Sitagliptin Phosphate | 47 | 12 |
| Torsemide | Torsemide | 46 | 15 |
| Trulicity | Dulaglutide | 45 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 44 | 11 |
| Alprazolam | Alprazolam | 43 | 15 |
| Lamotrigine | Lamotrigine | 43 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 41 | 11 |
| Ondansetron Odt | Ondansetron | 41 | 19 |
| Sumatriptan Succinate | Sumatriptan Succinate | 40 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 39 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Lansoprazole | Lansoprazole | 37 | 11 |
| Nystatin | Nystatin | 37 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 34 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 33 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 32 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Chlorthalidone | Chlorthalidone | 30 | suppressed |
| Fentanyl | Fentanyl | 30 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 30 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 29 | 11 |
| Prazosin Hcl | Prazosin Hcl | 29 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Invokana | Canagliflozin | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | 11 |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 25 |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Trulance | Plecanatide | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 17 |
| Carisoprodol | Carisoprodol | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 18 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Felodipine Er | Felodipine | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 11 |
| Epinephrine | Epinephrine | 14 | 12 |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 14 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 14 | suppressed |
| Nadolol | Nadolol | 14 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Euthyrox | Levothyroxine Sodium | 13 | suppressed |
| Metaxalone | Metaxalone | 13 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Prolia | Denosumab | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | 11 |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Constulose | Lactulose | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Levetiracetam Er | Levetiracetam | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,546.77 · 79 records | Lilly USA, LLC | ABRYSVO, AIRSUPRA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, Flector, GARDASIL 9, GEMTESA, Grastek, INSPIRE, KEVEYIS, Kerendia, Licart, MOUNJARO, NEFFY, NURTEC ODT, OTEZLA, Odactra, Ozempic, PAXLOVID, PREVNAR 20, REPATHA, ROTATEQ, Rybelsus, SIMPONI, SIMPONI ARIA, STELARA, TRELEGY ELLIPTA, TREMFYA, The Cologuard Plus Collection Kit, Tirosint, VAXELIS, VAXNEUVANCE, VOQUEZNA, Wegovy, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error